Prevalence of psoriasis in Brazil – a geographical survey

Romiti, Ricardo; Amone, Marcelo; Menter, Alan; Miot, Hélio Amante

doi:10.1111/ijd.13604

Cited by 58 publications

(58 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To obtain a representative sample, we randomly selected residential phone numbers and called them between 9 a.m and 8 p.m from Monday-Saturday during the months of January-June 2017 (Romiti, Amone, Menter, & Miot, 2017). Of those who could be reached, about 85% were willing to participate in the interview.…”

Section: Prevalence Of Vitiligo In Brazil-a Population Surveymentioning

confidence: 99%

Prevalence of vitiligo in Brazil—A population survey

Castro

Miot

2018

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

Section: Prevalence Of Vitiligo In Brazil-a Population Surveymentioning

confidence: 99%

Prevalence of vitiligo in Brazil—A population survey

Castro

Miot

2018

Pigment Cell Melanoma Res

View full text Add to dashboard Cite

“…There are several clinical variations of PsO; psoriasis vulgaris (also known as plaque psoriasis) is the most common (75–90%) . Disease prevalence is as high as 11.8% in several reports from different countries . A recent telephone survey estimates a prevalence of 1.3% in Brazil …”

Section: Introductionmentioning

confidence: 99%

“…1,[3][4][5] A recent telephone survey estimates a prevalence of 1.3% in Brazil. 6 The pathophysiology of PsO involves an interaction between inflammatory components, elements of the innate and adaptive immune response, and abnormal proliferation and differentiation of keratinocytes. 3 The immune-mediated feature characterizes PsO as a systemic illness that contributes to a greater frequency of comorbidities among affected subjects.…”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Souza

Castro

Carneiro

et al. 2018

The Journal of Dermatology

Self Cite

View full text Add to dashboard Cite

Interest has increased in comorbidities associated with psoriasis and their effects on health‐related quality of life (HRQoL). This study aimed to evaluate the prevalence of metabolic syndrome (MetS) and psoriatic arthritis (PsA) and to investigate HRQoL and the prevalence of hypertension, type 2 diabetes mellitus (T2DM), obesity and dyslipidemia. In a cross‐sectional design, patients diagnosed with plaque psoriasis answered an interview and standardized questionnaires (Dermatology Life Quality Index questionnaire [ DLQI ], 36‐Item Short Form Health Survey [SF‐36] and EuroQol Five‐Dimension Questionnaire Three‐Level version [ EQ ‐5D‐3L]). Physical examination and several tests to assess desired outcomes were performed by a dermatologist and a rheumatologist during three visits. The prevalence of MetS and PsA was 50.0% and 41.8%, respectively. Dyslipidemia was the most prevalent (74.5%) secondary comorbidity, followed by hypertension (61.8%), obesity (52.5%) and T2DM (30.9%). The mean (standard deviation) DLQI score was 6.5 (6.9), and mean physical and mental SF‐36 measures were 45.2 (10.4) and 45.5 (12.3), respectively, and for EQ‐5D‐3L, mean utility index and EQ ‐ VAS scores were 0.68 (0.27) and 72.7 (19.7), respectively. PsA and MetS are important comorbidities; a reduced HRQoL is noted among plaque psoriasis patients with these comorbidities, emphasizing the relevance of diagnosis and treatment beyond the care of skin lesions.

show abstract

“…A psoríase é uma doença de pele inflamatória crônica, imunomediada, multissistêmica, com comorbidades associadas (Golbari et al, 2018;Sociedade Brasileira de Dermatologia, 2012; National Institute for Health and Clinical Excellence, 2012), que acomete homens e mulheres de todas as idades, porém com picos de incidência aos 20 e 50 anos (Sociedade Brasileira de Dermatologia, 2012). A prevalência da psoríase pode variar, mas estima-se que seja de 2% a 4% na população ocidental e de 1,31% na população brasileira (Golbari et al, 2018;Sociedade Brasileira de Dermatologia, 2012;Romiti et al, 2017). Características genéticas, étnicas, geográficas e ambientais podem influenciar no acometimento pela doença (Sociedade Brasileira de Dermatologia, 2012).…”

Section: Introductionunclassified

Análise de custo por resposta de adalimumabe, etanercepte, guselcumabe, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe para tratamento de psoríase em placas moderada a grave sob a perspectiva do Sistema de Saúde Suplementar brasileiro

Fioratti¹,

Valencia-Mendoza²,

Rachid³

et al. 2018

JBES

View full text Add to dashboard Cite

Objetivo: O objetivo deste estudo é avaliar o custo por resposta das terapias biológicas disponíveis no Brasil para o tratamento da psoríase em placas moderada a grave na perspectiva do Sistema de Saúde Suplementar. Métodos: A resposta PASI 90 foi o desfecho avaliado neste estudo. Dados clínicos foram calculados com base na razão de risco de uma metanálise em rede, comparando adalimumabe, etanercepte, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe a guselcumabe, cujo dado foi obtido no estudo clínico. Foram considerados apenas os custos de medicamentos. O caso-base avaliou o custo por resposta do ano de indução do tratamento. Além disso, conduziu-se uma análise de orçamento fixo. Em um cenário alternativo, analisou-se o custo por resposta do ano de manutenção. Uma análise de sensibilidade avaliou incertezas dos dados clínicos. Resultados: O menor custo por resposta foi de guselcumabe

show abstract

Prevalence of psoriasis in Brazil – a geographical survey

Cited by 58 publications

References 7 publications

Prevalence of vitiligo in Brazil—A population survey

Prevalence of vitiligo in Brazil—A population survey

Metabolic syndrome and psoriatic arthritis among patients with psoriasis vulgaris: Quality of life and prevalence

Análise de custo por resposta de adalimumabe, etanercepte, guselcumabe, infliximabe, ixequizumabe, secuquinumabe e ustequinumabe para tratamento de psoríase em placas moderada a grave sob a perspectiva do Sistema de Saúde Suplementar brasileiro

Contact Info

Product

Resources

About